Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 8.33 percent increase over losses of $(0.12) per share from the same period last year.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2023 | $8.00 | Buy | Citigroup |
| 4/24/2023 | $9.00 | Buy | H.C. Wainwright |
| 4/14/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 4/8/2022 | $19.00 | Overweight | Piper Sandler |
| 4/4/2022 | $21.00 | Buy | Citigroup |
Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00
H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $20.00
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
No Severe Long-Term Toxicities With 2-Year Local Recurrence-Free Survival At 77%
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company's Board of Directors in order to assume the full-time position of Alpha Tau's Chief Commercial Officer. Mr. Melnyk served most recently as CEO of Fortovia Therapeutics, an oncology supportive care pharmaceutical and medical device company headquartered in Raleigh, North Carolina. Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure
JERUSALEM, June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) (NASDAQ:DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Mr. Gary Leibler has resigned from the Company's board of directors and its audit committee, for reasons unrelated to the Company. "I wish to thank Gary for his years of dedicated service to the Company, as a member of the board of directors since the early days of Alpha Tau," commented Alpha Tau CEO Uzi Sofer. "He has added tremendous value ever since his first day with us, and we have benefitted greatly from his expertise and experience." Gary Leibler, who also serves as
JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti
JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, announced today that it has been accepted into the prestigious Total Product Life Cycle (TPLC) Advisory Program ("TAP") Pilot of the U.S. Food and Drug Administration ("FDA"), to accelerate market access to the Alpha DaRT for patients with recurrent glioblastoma multiforme ("GBM"). This acceptance follows the Company's previous receipt of Breakthrough Device Designation from the FDA for this indication, one of two such designations received for the Alpha DaRT, and a pre-requisite for applicati
JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that its first patient with recurrent lung cancer has been treated, in a clinical trial at Hadassah Medical Center in Jerusalem, Israel. The trial is designed to treat up to ten patients with recurrent tumors in the mediastinum area of the chest, and allows for the use of concurrent chemotherapy, targeted therapy, or immunotherapy, if indicated. The study will assess the safety and feasibility of delivering Alpha DaRT sources into the lung using an endobronchial ultrasound (EB
JERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using the Alpha DaRT. The clinical study, which is an investigator-initiated study led by the Winship Cancer Institute of Emory University in Atlanta, has been approved to enroll up to 28 U.S. patients at up to 8 institutions i